#stomca - Twitter Hashtag

over 1 year ago

Second-line treatment with T-DXd significantly increased OS vs ramucirumab plus paclitaxel in patients with HER2+ gastric/GEJ adenocarcinoma. #stomca #oncology #MedEd https://t.co/qO7ekHDpKN

OncLive's tweet photo. Second-line treatment with T-DXd significantly increased OS vs ramucirumab plus paclitaxel in patients with HER2+ gastric/GEJ adenocarcinoma. #stomca #oncology #MedEd https://t.co/qO7ekHDpKN https://t.co/fErABkH8Xs

0

7

4

1

1K

OncLive.com

@OncLive

over 1 year ago

In the DESTINY-Gastric04 trial, T-DXd improved OS among patients with unresectable/metastatic HER2+ gastric/GEJ adenocarcinoma following a trastuzumab-containing regimen. #stomca #oncology #MedEd https://t.co/qO7ekHDpKN

0

10

2

1

754

OncLive.com

@OncLive

over 1 year ago

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC @ASCO #GI25 #stomca https://t.co/JoLSlHylfh

0

7

2

4

1K

OncLive.com

@OncLive

over 1 year ago

Here's a snapshot of our time covering this year's ASCO #GI25 meeting, featuring some of the incredible KOLs we spoke with and key research discussed. Stay tuned for more post-conference coverage! @ASCO #stomca #crcsm #pancsm #oncology

0

3

0

675

OncLive.com

@OncLive

over 1 year ago

HR-1701 Plus Chemo Reduces Myelosuppression in HER2-Negative Gastric and GEJ Adenocarcinoma @ASCO #GI25 #stomca #oncology https://t.co/iDQYTYdaMf

0

3

0

528

OncLive.com

@OncLive

over 1 year ago

Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer @ASCO #GI25 #stomca #oncology https://t.co/qujObVgNqZ

0

3

1

0

553

OncLive.com

@OncLive

over 1 year ago

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer @ASCO #GI25 #stomca #oncology https://t.co/FNH1NnXcm8

0

4

1

764

OncLive.com

@OncLive

over 1 year ago

Check out this quick recap of key @US_FDA approvals in #oncology during November 2024, featuring expert insights on their implications for clinical practice! For more information, read the article linked below: https://t.co/e2v6l1UWT8 #MedEd #MedTwitter #leusm #lymsm #stomca

0

3

0

630

OncLive.com

@OncLive

over 1 year ago

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024. @UCSFCancer #oncology #stomca https://t.co/XSA4CkzTcN

0

4

3

1

721

OncLive.com

@OncLive

over 1 year ago

Ushering more targeted therapies into the 2024 updates to the NCCN Clinical Practice Guidelines in Oncology for biliary tract cancers represented a notable advancement in the GI cancer space. @UCSFCancer #oncology #stomca https://t.co/XSA4CkzTcN

OncLive's tweet photo. Ushering more targeted therapies into the 2024 updates to the NCCN Clinical Practice Guidelines in Oncology for biliary tract cancers represented a notable advancement in the GI cancer space. @UCSFCancer #oncology #stomca https://t.co/XSA4CkzTcN https://t.co/dwpB2NeN99

0

4

1

905

OncLive.com

@OncLive

almost 2 years ago

The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer. #oncology #stomca https://t.co/6aBqIj8mkI

OncLive's tweet photo. The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer. #oncology #stomca https://t.co/6aBqIj8mkI https://t.co/ZsvjYxQcVO

0

3

0

679

OncLive.com

@OncLive

almost 2 years ago

Trastuzumab deruxtecan elicited responses in patients with HER2-positive biliary tract cancer, according to data from a single-arm, phase 2 trial. #stomca #oncology https://t.co/IY3fnTLxEP

0

1

0

881

OncLive.com

@OncLive

almost 2 years ago

T-DXd elicited a confirmed ORR of 36.4% by BICR in Japanese patients with HER2-positive biliary tract cancer, meeting the primary end point of the single-arm, phase 2 HERB study. #stomca #oncology https://t.co/IY3fnTLxEP

0

7

1

0

803

OncLive.com

@OncLive

about 2 years ago

The addition of lunresertib to FOLFIRI elicited responses in heavily pretreated patients with locally advanced or metastatic GI solid tumors harboring CCNE1 amplifications or deleterious FBXW7 alterations. #ESMOGI24 #oncology #stomca @myESMO https://t.co/vyDVB9Z2fi

1

0

1K

OncLive.com

@OncLive

about 2 years ago

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer #stomca #oncology #ESMOGI24 @myESMO https://t.co/dNCylHzk5q

0

4

0

829

OncLive.com

@OncLive

about 2 years ago

Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors #ESMOGI24 #oncology #stomca @myESMO https://t.co/vyDVB9Z2fi

0

1

0

837

Dr.Nitin Yashas

@drnitinyashas

over 2 years ago

Happy to share our single centre experience of molecular testing in Stage 4 Stomach cancer in India. Her2 positivity of 16% & MMR deficiency of 8% opens up Rx options. @OncLive @OncoAlert @OncBrothers #CancerResearch #stomca #gicsm #gastriccancer https://t.co/SqCfTW7c6W

1

4

1

0

241

ESDO @ESDO_tweets

about 3 years ago

👉 Our visual bulletin of GI Oncology is out (May 2023)❗️ 💥Now you won't miss any major publication in the field❗️ #oncology #crcsm #esophca #hpbcsm #pancsm #stomca https://t.co/ujrPosU6Ht

ESDO_tweets's tweet photo. 👉 Our visual bulletin of GI Oncology is out (May 2023)❗️
💥Now you won't miss any major publication in the field❗️

#oncology #crcsm #esophca #hpbcsm #pancsm #stomca
https://t.co/ujrPosU6Ht https://t.co/2JC30fSrBi

1

3

2

1

483

Top Tweets for #stomca

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users